AstraZeneca Pharmaceuticals LPUsage: BRILINTA is indicated for reducing the risk of cardiovascular death, myocardial infarction, and stroke in patients with acute coronary syndrome or a history of myocardial infarction, as well as for those with high-risk coronary artery disease. It also decreases stroke risk in patients with acute ischemic stroke or transient ischemic attack.